Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Follow-Up Questions
Who is the CEO of Korro Bio Inc?
Dr. Ram Aiyar is the President of Korro Bio Inc, joining the firm since 2023.
What is the price performance of KRRO stock?
The current price of KRRO is $34.55, it has decreased 6.15% in the last trading day.
What are the primary business themes or industries for Korro Bio Inc?
Korro Bio Inc belongs to Biotechnology industry and the sector is Health Care
What is Korro Bio Inc market cap?
Korro Bio Inc's current market cap is $324.4M
Is Korro Bio Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Korro Bio Inc, including 5 strong buy, 10 buy, 1 hold, 0 sell, and 5 strong sell
